Arrowhead Pharmaceuticals
 | |
| Company type | Biopharmaceutical |
|---|---|
| Nasdaq: ARWR Russell 2000 Component | |
| Founded | 1 January 2004  |
| Headquarters | Pasadena, CA |
Key people | Christopher Anzalone, Ph.D., president and chief executive officer
Bruce Given, M.D., chief operating officer Ken Myszkowski, MBA, CPA, chief financial officer |
| Website | http://arrowheadpharma.com/ |
Arrowhead Pharmaceuticals is a publicly traded (NASDAQ: ARWR) biopharmaceutical company based in Pasadena, California. Arrowhead’s products in development act through RNA interference (RNAi) mechanisms of action.[1][2] The company focuses on treatments for Hepatitis B, the liver disease associated with alpha 1-antitrypsin deficiency (AATD) and cardiovascular disease.[1] The company has eight products in its pipeline, in various stages of development.[1]
| Product | Indication | Development phase | |
|---|---|---|---|
| ARO-HBV[1] | Hepatitis B | In Clinic Phase 1/2 | |
| ARO-AAT[1] | Alpha-1 Antirypsin Deficiency | In Clinic Phase 1/2 | |
| ARO-APOC3[1] | Hypertriglyceridemia | Pre-Clinical | |
| ARO-HIF2[1] | Renal Cell Carcinoma | Pre-Clinical | |
| ARO-LUNG1[1] | Undisclosed | Pre-Clinical | |
| ARO-ANG3[1] | Hypertriglyceridemia | Pre-Clinical | |
| ARO-LPA[1] | Cardiovascular Disease | Pre-Clinical | Partnered with Amgen |
| ARO-AMG1[1] | Undisclosed Cardiovascular | Pre-Clinical | Partnered with Amgen |
In 2015, the company substantially expanded its intellectual property holdings through complete acquisition of the full RNAi research and development portfolio and assets from Novartis.[3][4]
In September 2016, Arrowhead entered into two collaboration and licensing agreements with Amgen. Under the deals, Amgen received a worldwide exclusive license to Arrowhead’s ARO-LPA RNAi program and an option to a worldwide exclusive license for ARO-AMG1, both for cardiovascular disease.[5]
References
- ^ a b c d e f g h i j k "arwr-10q_20170331.htm". www.sec.gov. Retrieved 2017-05-17.
- ^ "8-K". www.sec.gov. Retrieved 2017-05-17.
- ^ "Arrowhead buys Novartis' RNAi portfolio". Reuters. 2017-03-05. Retrieved 2017-05-17.
- ^ Staff (1 April 2015). "Novartis Sells RNAi R&D Portfolio to Arrowhead in $35M Agreement". News: Industry Watch. Genetic Engineering & Biotechnology News (Paper). 35 (7): 10.
- ^ "Amgen, Arrowhead team up on gene-therapies for heart disease". Reuters. 2017-09-29. Retrieved 2017-05-17.